SBIR/STTR Research Award
Targeted siRNA NanoJackets for the Personalized Treatment of Breast Cancer
Award amount
$223,896Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- KEYSTONE NANO, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- M5STD1CK7FC3
- Solicitation number
- PAR10-286
- Topic code
- NCI
Research abstract
DESCRIPTION (provided by applicant): Most current chemotherapeutics have non-specific mechanisms of action and poor biodistribution profiles which result in dose-limiting toxicities tha prevent optimal efficacy from being obtained. Ribonucleic acid interference (RNAi) has the potential to be a safe, selective and personalized treatment approached for a variety of genetic-based diseases, including cancer. In particular, the design of small interfering RNA (siRNA) sequences to prevent the expression of cancer-fueling mutations provides an alternative to current therapeutic approaches. However, an effective delivery vehicle is required for systemic RNAi therapy to protect siRNA during circulation, concentrate siRNA at tumor sites and mediate cellular uptake aswell as endosomal escape. This project is designed to optimize a novel, combinatorial RNAi treatment for advanced breast cancer based on delivery by calcium phosphate nanoparticles, called NanoJackets. Building on the demonstrated in vivo efficacy of
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Ceraxa (Ceramide NanoLiposome) and Vinblastine For the Improved Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Clinical Investigation of the Ceramide NanoLiposome for Advanced Solid Tumors
- IGF OT IGF "DEVELOPMENT OF SIRNA NANOJACKETS FOR RNAI BASED INFLUENZA TREATMENT"
- MULTIFUNCTIONAL NANOJACKETS FOR BREAST CANCER TREATMENT
- Targeting NanoJacketed Doxorubicin to Tumor Sites for Improved Treatment of Breas
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
6 SBIR/STTR records share this UEI (2009–2022). Reported award amounts total $4,750,831. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services